Superficial Spreading Melanoma

What Is Superficial Spreading Melanoma

Superficial spreading melanoma is the most common subtype of cutaneous melanoma, accounting for approximately 70 percent of all melanoma diagnoses in fair-skinned populations. It arises from melanocytes, the pigment-producing cells of the skin, and is distinguished by an initial radial growth phase in which the lesion expands horizontally across the epidermis before invading deeper layers.

The term radial growth phase describes the period when malignant melanocytes spread laterally within the epidermis and the papillary dermis without forming a true invasive nodule. During this phase, which may last months to years, the lesion often appears as a slowly enlarging, irregularly pigmented patch. If unchecked, the tumor eventually transitions to a vertical growth phase, in which cells penetrate the reticular dermis and acquire the capacity to metastasize. This biphasic growth pattern is a hallmark of the subtype and underpins the clinical emphasis on early detection.

Unlike nodular melanoma, which often presents as a rapidly growing dome-shaped nodule with minimal radial spread, superficial spreading melanoma typically evolves through a recognizable flat or slightly elevated phase. This window of opportunity allows clinicians and patients to identify suspicious lesions before deep invasion occurs. The lesion may remain in situ, confined to the epidermis, for a variable period before becoming invasive.

Who Is Typically Affected

Superficial spreading melanoma most frequently affects adults between the ages of 30 and 60, with a median age at diagnosis in the early 50s. It is rare before puberty and becomes progressively more common with advancing age. Men and women are affected in roughly equal numbers overall, though anatomic distribution differs by sex, as detailed below.

Skin phototype is a major determinant of risk. Individuals with Fitzpatrick skin types I and II — fair skin that burns easily, freckles, and tans poorly — carry the highest susceptibility. Red or blond hair, light-colored eyes, and a high density of common or atypical nevi (moles) further increase risk. A personal or family history of melanoma approximately doubles the likelihood of developing the disease.

Ultraviolet (UV) radiation exposure, particularly intermittent intense sun exposure leading to sunburns during childhood and adolescence, is the principal environmental risk factor. Chronic occupational sun exposure appears less strongly linked to this subtype than to lentigo maligna melanoma. Indoor tanning device use before age 35 has been associated with a 59 percent increase in melanoma risk in meta-analyses of case-control studies.

Immunosuppression, whether iatrogenic following organ transplantation or due to conditions such as HIV infection, elevates melanoma risk and may be associated with more aggressive behavior. However, the majority of patients have no identifiable immunosuppressive condition.

Clinical Appearance: Recognizing the Lesion

The clinical hallmark of superficial spreading melanoma is an asymmetric, irregularly bordered macule or thin plaque with variable pigmentation. The ABCDE criteria — Asymmetry, Border irregularity, Color variation, Diameter greater than 6 millimeters, and Evolution — were developed specifically to aid recognition of this subtype.

Asymmetry refers to the inability to superimpose one half of the lesion onto the other through any axis. Border irregularity manifests as notched, scalloped, or poorly defined margins that fade imperceptibly into surrounding skin. Color variation is often striking: shades of tan, brown, black, red, white, and blue-gray may coexist within a single lesion, reflecting areas of regression, hyperkeratosis, or varying melanin depth. Diameter exceeding 6 millimeters (approximately the size of a pencil eraser) is a traditional threshold, though smaller lesions can be malignant and larger ones benign. Evolution — change in size, shape, color, elevation, or the onset of symptoms such as itching or bleeding — is the single most sensitive indicator.

The ugly duckling sign complements ABCDE: a lesion that looks distinctly different from a patient’s other nevi warrants scrutiny even if it does not meet formal ABCDE criteria. This concept acknowledges that individuals have a characteristic “nevus phenotype,” and outliers deserve attention.

Ordinary acquired nevi are typically symmetric, uniformly colored, sharply demarcated, and smaller than 6 millimeters. They tend to be stable over time. Congenital nevi may be larger but usually retain symmetry and regular borders. Dysplastic (atypical) nevi share some features with melanoma — irregular borders, color variegation — but generally lack the marked asymmetry and chaotic architecture of malignancy. Dermoscopy helps resolve this distinction, as described below.

Anatomic Distribution

Superficial spreading melanoma shows a predilection for intermittently sun-exposed skin. In men, the trunk — particularly the upper back — is the most common site. In women, the lower extremities, especially the legs, predominate. This sex difference likely reflects historical patterns of recreational sun exposure and clothing habits.

The head and neck, upper arms, and shoulders are also frequent locations. Lesions on the palms, soles, and nail units are rare for this subtype; those sites are more characteristic of acral lentiginous melanoma. Mucosal surfaces are not a typical site for superficial spreading melanoma.

A notable feature is the association with pre-existing nevi. Approximately 20 to 30 percent of superficial spreading melanomas arise in association with a pre-existing nevus, identifiable by a residual nevus component at the lesion’s periphery. The majority, however, arise de novo on previously normal-appearing skin.

Pathogenesis: From Melanocyte to Invasive Tumor

Melanocytes originate from neural crest cells and reside in the basal layer of the epidermis, where they transfer melanin to surrounding keratinocytes. In superficial spreading melanoma, a series of genetic alterations — most commonly BRAF V600E mutations (present in approximately 50 percent of cases), NRAS mutations (15 to 20 percent), and NF1 loss — drive uncontrolled proliferation and survival of transformed melanocytes.

During the radial growth phase, malignant melanocytes spread within the epidermis singly or in small nests, often extending beyond the dermal-epidermal junction into the papillary dermis. This intraepidermal spread may persist for months to years. The lesion is typically flat or minimally elevated. Histologically, pagetoid spread — upward migration of atypical melanocytes into the upper epidermal layers — is a characteristic feature.

Transition to the vertical growth phase marks the acquisition of invasive potential. Tumor cells form expansile nodules in the reticular dermis, express distinct adhesion molecules, and lose dependence on keratinocyte-derived growth factors. The depth of invasion, measured as Breslow thickness from the granular layer of the epidermis to the deepest invasive cell, is the single most important prognostic factor. A thickness of less than 0.8 millimeters without ulceration carries an excellent prognosis; thicker tumors correlate with progressively higher metastatic risk.

Ulceration — loss of the epidermal covering over the tumor — independently worsens prognosis at any given thickness and upstages the tumor in the AJCC staging system. Mitotic rate (number of mitoses per square millimeter) provides additional prognostic information, particularly for thin tumors.

Diagnostic Approach

Diagnosis begins with a thorough skin examination under good lighting, often aided by a dermatoscope — a handheld device that provides 10-fold magnification and polarized or non-polarized light to visualize subsurface structures invisible to the naked eye. Dermoscopy has become standard of care for pigmented lesion evaluation and significantly improves diagnostic accuracy compared with unaided visual inspection.

Characteristic dermoscopic features of superficial spreading melanoma include an atypical pigment network (irregular, thickened, or abruptly terminating lines), irregular streaks or pseudopods at the periphery, blue-white veil (indicating regression or compact orthokeratosis overlying melanin deep in the dermis), regression structures (white scar-like areas and blue-gray peppering), and polymorphous vascular patterns. The chaos and clues algorithm and the three-point checklist (asymmetry in structure or color, atypical network, blue-white structures) are widely used diagnostic frameworks.

When a lesion is suspicious, the gold standard for diagnosis is excisional biopsy with narrow clinical margins (typically 1 to 3 millimeters) that includes the full thickness of the skin and subcutaneous fat. This allows accurate measurement of Breslow thickness and assessment of ulceration, mitotic rate, and peripheral and deep margins. Partial biopsies (shave, punch) are discouraged for lesions suspicious for melanoma because they may underestimate thickness or miss ulceration, though they are sometimes unavoidable for large lesions or cosmetically sensitive sites.

Histopathology confirms the diagnosis. The pathologist evaluates architectural disorder, cytologic atypia, pagetoid spread, dermal invasion, mitotic figures, and the presence or absence of a pre-existing nevus. Immunohistochemical stains (S100, SOX10, Melan-A, HMB-45, Ki-67) may assist in difficult cases. Molecular testing for BRAF, NRAS, KIT, or NF1 alterations is not routinely performed for early-stage disease but informs systemic therapy selection for advanced melanoma.

Staging in Plain Language

The American Joint Committee on Cancer (AJCC) 8th edition staging system classifies cutaneous melanoma based on primary tumor characteristics (T), regional lymph node involvement (N), and distant metastasis (M). For superficial spreading melanoma, the T category is determined primarily by Breslow thickness and ulceration status.

N categories reflect regional lymph node involvement: N0 indicates no nodal metastasis; N1–N3 indicate increasing numbers of involved nodes or the presence of in-transit, satellite, or microsatellite metastases. M categories distinguish M0 (no distant spread) from M1a–M1d (metastasis to skin/subcutaneous tissue/lymph nodes, lung, other visceral sites, or central nervous system, respectively, with or without elevated lactate dehydrogenase).

Stage grouping combines T, N, and M: Stage 0 is melanoma in situ. Stage I and II are localized disease of increasing thickness and ulceration status. Stage III indicates regional nodal or in-transit spread. Stage IV denotes distant metastasis. Accurate staging guides treatment decisions and prognosis discussions.

Treatment Overview

Treatment of localized superficial spreading melanoma centers on complete surgical excision of the primary tumor with histologically negative margins. The recommended excision margin width correlates with Breslow thickness, based on randomized controlled trials and meta-analyses.

For tumors thicker than 0.8 mm (or thinner with ulceration or other adverse features), sentinel lymph node biopsy (SLNB) is routinely discussed and offered. This procedure identifies the first lymph node(s) draining the primary tumor site using lymphatic mapping with radiocolloid and/or blue dye. If the sentinel node is negative, no further nodal surgery is typically performed. If positive, completion lymph node dissection was historically standard, but recent trials (MSLT-II, DeCOG-SLT) have shown that observation with ultrasound surveillance is a reasonable alternative for many patients, sparing the morbidity of full dissection.

Adjuvant systemic therapy — immune checkpoint inhibitors (anti-PD-1 agents such as pembrolizumab or nivolumab) or targeted therapy (BRAF/MEK inhibitors for BRAF-mutant disease) — is considered for resected Stage III disease and select high-risk Stage IIB/IIC (thickness > 2 mm or > 4 mm, respectively, with or without ulceration). These therapies reduce recurrence risk but carry immune-related or targeted toxicities. The decision involves multidisciplinary discussion weighing recurrence risk, patient comorbidities, and preferences.

For unresectable Stage III or Stage IV disease, systemic therapy is the mainstay. Immune checkpoint inhibitors, either alone or in combination (anti-CTLA-4 plus anti-PD-1), and BRAF/MEK inhibitor combinations for BRAF-mutant melanoma have transformed outcomes, with long-term survival now achievable for a subset of patients. Radiation therapy may play a role for local control after nodal dissection or for brain metastases. Treatment of advanced melanoma is highly individualized and rapidly evolving.

Outlook and Prognosis

Prognosis for superficial spreading melanoma is strongly tied to stage at diagnosis. Population-based registry data provide approximate survival figures that reflect groups, not individual outcomes. These statistics derive from patients diagnosed in earlier treatment eras and may not fully reflect current outcomes with modern adjuvant and systemic therapies.

Favorable prognostic features include female sex, younger age, extremity primary site (versus trunk or head/neck), absence of ulceration, lower mitotic rate, and lack of microsatellitosis. BRAF mutation status does not independently predict prognosis but guides targeted therapy eligibility.

It is essential to emphasize that these are population averages. Individual outcomes depend on tumor biology, host immunity, access to care, and treatment response. Many patients with thicker primaries or nodal involvement are cured; some with thin primaries recur. Ongoing surveillance is critical for all patients.

Follow-Up and Long-Term Skin Surveillance

After treatment for superficial spreading melanoma, patients enter a structured follow-up program. The primary goals are early detection of local recurrence, in-transit or nodal metastasis, new primary melanomas, and management of treatment-related effects. Follow-up intensity and duration are guided by stage.

For Stage 0–IA disease, typical follow-up involves a full skin examination every 6 to 12 months for at least 5 years, then annually thereafter. For Stage IB–IIC, examinations every 3 to 6 months for the first 2 to 3 years, then every 6 to 12 months to 5 years, then annually. For Stage III, examinations every 3 to 4 months for the first 2 to 3 years, then every 6 months to 5 years, then annually. Imaging surveillance (CT, PET-CT, or MRI) is generally reserved for Stage IIIB–IIIC and Stage IV, or when symptoms or signs suggest recurrence.

Patients are taught skin self-examination using the ABCDE and ugly duckling concepts. Photographic documentation (total body photography) and sequential digital dermoscopy imaging are valuable adjuncts for patients with numerous atypical nevi or a strong personal or family history. These tools help detect new or changing lesions that might be missed on clinical examination alone.

Sun protection remains a cornerstone of long-term management: broad-spectrum sunscreen (SPF 30 or higher), protective clothing, wide-brimmed hats, seeking shade during peak UV hours (10 AM to 4 PM), and avoidance of indoor tanning. Vitamin D supplementation may be appropriate for patients practicing strict sun avoidance; serum 25-hydroxyvitamin D levels can guide dosing.

Psychosocial support addresses anxiety about recurrence, body image concerns after surgery, and the burden of lifelong surveillance. Patient advocacy organizations and melanoma support groups provide valuable peer connection and practical resources.

Comparison With Other Melanoma Subtypes

Superficial spreading melanoma is one of four major histologic subtypes of cutaneous melanoma. Understanding the distinctions aids recognition and underscores that melanoma is not a single disease.

Desmoplastic melanoma and melanoma arising in congenital nevi are less common variants with distinct features. The above table reflects typical patterns; individual cases may vary.

Resources

1. National Cancer Institute. Melanoma Treatment (PDQ) – Health Professional Version. Bethesda, MD: NCI; 2024. Available at: https://www.cancer.gov/types/skin/hp/melanoma-treatment-pdq Accessed: 27 August 2026.
2. American Cancer Society. Melanoma Skin Cancer. Atlanta, GA: ACS; 2024. Available at: https://www.cancer.org/cancer/melanoma-skin-cancer.html Accessed: 27 August 2026.
3. American Academy of Dermatology. Melanoma: Diagnosis and Treatment. Rosemont, IL: AAD; 2023. Available at: https://www.aad.org/public/diseases/skin-cancer/melanoma Accessed: 27 August 2026.
4. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–492. Available at: https://doi.org/10.3322/caac.21409 Accessed: 27 August 2026.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Cutaneous Melanoma. Version 2.2024. Plymouth Meeting, PA: NCCN; 2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf Accessed: 27 August 2026.
6. World Health Organization / International Agency for Research on Cancer. Melanoma of Skin. In: WHO Classification of Tumours: Skin Tumours. 5th ed. Lyon: IARC; 2023. Available at: https://publications.iarc.fr/608 Accessed: 27 August 2026.
7. Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies for melanoma. Nat Rev Clin Oncol. 2017;14(8):463–482. Available at: https://doi.org/10.1038/nrclinonc.2017.43 Accessed: 27 August 2026.
8. Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211–2222. Available at: https://doi.org/10.1056/NEJMoa1613210 Accessed: 27 August 2026.
9. Eggermont AMM, Blank CU, Mandalà M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–1801. Available at: https://doi.org/10.1056/NEJMoa1802357 Accessed: 27 August 2026.
10. Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813–1823. Available at: https://doi.org/10.1056/NEJMoa1708539 Accessed: 27 August 2026.
11. Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol. 2002;3(3):159–165. Available at: https://doi.org/10.1016/S1470-2045(02)00679-4 Accessed: 27 August 2026.
12. Argenziano G, Fabbrocini G, Carli P, et al. Epiluminescence microscopy for the diagnosis of doubtful melanocytic skin lesions: comparison of the ABCD rule of dermatoscopy and a new 7-point checklist. J Am Acad Dermatol. 1998;38(1):72–78. Available at: https://doi.org/10.1016/S0190-9622(98)70455-5 Accessed: 27 August 2026.
13. Whiteman DC, Green AC, Olsen CM. The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031. J Invest Dermatol. 2016;136(6):1161–1166. Available at: https://doi.org/10.1016/j.jid.2016.01.035 Accessed: 27 August 2026.
14. Cancer Research UK. Melanoma Skin Cancer Statistics. London: CRUK; 2024. Available at: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/melanoma-skin-cancer Accessed: 27 August 2026.